ID   CP21A_HUMAN             Reviewed;         494 AA.
AC   P08686; A2BHY6; P04033; Q01204; Q08AG8; Q16749; Q16806; Q5ST44; Q96NU8;
DT   01-NOV-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1988, sequence version 1.
DT   28-JUN-2023, entry version 238.
DE   RecName: Full=Steroid 21-hydroxylase {ECO:0000303|PubMed:25855791};
DE            EC=1.14.14.16 {ECO:0000269|PubMed:16984992, ECO:0000269|PubMed:22014889, ECO:0000269|PubMed:25855791, ECO:0000269|PubMed:27721825};
DE   AltName: Full=21-OHase;
DE   AltName: Full=Cytochrome P-450c21;
DE   AltName: Full=Cytochrome P450 21;
DE   AltName: Full=Cytochrome P450 XXI;
DE   AltName: Full=Cytochrome P450-C21;
DE   AltName: Full=Cytochrome P450-C21B;
GN   Name=CYP21A2; Synonyms=CYP21, CYP21B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE CYP21A2*1A).
RX   PubMed=3486422; DOI=10.1073/pnas.83.9.2841;
RA   Higashi Y., Yoshioka H., Yamane M., Gotoh O., Fujii-Kuriyama Y.;
RT   "Complete nucleotide sequence of two steroid 21-hydroxylase genes tandemly
RT   arranged in human chromosome: a pseudogene and a genuine gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:2841-2845(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ALLELE CYP21A2*1B) (ISOFORM 1).
RX   PubMed=3487786; DOI=10.1073/pnas.83.14.5111;
RA   White P.C., New M.I., Dupont B.;
RT   "Structure of human steroid 21-hydroxylase genes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:5111-5115(1986).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANT AH3 THR-268, VARIANTS LEU-9 INS;
RP   ARG-102 AND SER-493, AND INVOLVEMENT IN AH3.
RX   PubMed=3038528; DOI=10.1002/j.1460-2075.1987.tb02414.x;
RA   Rodrigues N.R., Dunham I., Yu C.Y., Carroll M.C., Porter R.R.,
RA   Campbell R.D.;
RT   "Molecular characterization of the HLA-linked steroid 21-hydroxylase B gene
RT   from an individual with congenital adrenal hyperplasia.";
RL   EMBO J. 6:1653-1661(1987).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANT AH3 LEU-281, AND VARIANT LEU-9
RP   INS.
RX   PubMed=3267225; DOI=10.1172/jci113562;
RA   Globerman H., Amor M., Parker K.L., New M.I., White P.C.;
RT   "Nonsense mutation causing steroid 21-hydroxylase deficiency.";
RL   J. Clin. Invest. 82:139-144(1988).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANTS LEU-9 INS; ARG-102 AND SER-493,
RP   AND VARIANTS AH3 HIS-339 AND SER-453.
RC   TISSUE=Peripheral blood;
RX   PubMed=1406709; DOI=10.1210/mend.6.8.1406709;
RA   Helmberg A., Tusie-Luna M.-T., Tabarelli M., Kofler R., White P.C.;
RT   "R339H and P453S: CYP21 mutations associated with nonclassic steroid 21-
RT   hydroxylase deficiency that are not apparent gene conversions.";
RL   Mol. Endocrinol. 6:1318-1322(1992).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=19505723; DOI=10.1016/j.molimm.2009.04.033;
RA   Blasko B., Banlaki Z., Gyapay G., Pozsonyi E., Sasvari-Szekely M.,
RA   Rajczy K., Fust G., Szilagyi A.;
RT   "Linkage analysis of the C4A/C4B copy number variation and polymorphisms of
RT   the adjacent steroid 21-hydroxylase gene in a healthy population.";
RL   Mol. Immunol. 46:2623-2629(2009).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ALLELE CYP21A2*6) (ISOFORM 2).
RC   TISSUE=Adrenal gland;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT SER-493.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 109-185, AND VARIANT AH3 ASN-172.
RX   PubMed=8485582; DOI=10.1038/ng0393-260;
RA   Collier S., Tassabehji M., Sinnott P., Strachan T.;
RT   "A de novo pathological point mutation at the 21-hydroxylase locus:
RT   implications for gene conversion in the human genome.";
RL   Nat. Genet. 3:260-265(1993).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 149-182, AND VARIANT AH3 ASN-172.
RX   PubMed=3871526; DOI=10.1073/pnas.82.2.521;
RA   Carroll M.C., Campbell R.D., Porter R.R.;
RT   "Mapping of steroid 21-hydroxylase genes adjacent to complement component
RT   C4 genes in HLA, the major histocompatibility complex in man.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:521-525(1985).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 149-182, AND VARIANT AH3 ASN-172.
RX   PubMed=3257825; DOI=10.1073/pnas.85.5.1600;
RA   Amor M., Parker K.L., Globerman H., New M.I., White P.C.;
RT   "Mutation in the CYP21B gene (Ile-172-->Asn) causes steroid 21-hydroxylase
RT   deficiency.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:1600-1604(1988).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 265-494 (ISOFORM 1), AND VARIANT AH3 LEU-281.
RX   PubMed=3497399; DOI=10.1073/pnas.84.16.5858;
RA   Matteson K.J., Phillips J.A. III, Miller W.L., Chung B.C., Orlando P.J.,
RA   Frisch H., Ferrandez A., Burr I.M.;
RT   "P450XXI (steroid 21-hydroxylase) gene deletions are not found in family
RT   studies of congenital adrenal hyperplasia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:5858-5862(1987).
RN   [15]
RP   FUNCTION.
RX   PubMed=10602386; DOI=10.1038/sj.gt.3301018;
RA   Tajima T., Okada T., Ma X.M., Ramsey W., Bornstein S., Aguilera G.;
RT   "Restoration of adrenal steroidogenesis by adenovirus-mediated transfer of
RT   human cytochromeP450 21-hydroxylase into the adrenal gland of21-
RT   hydroxylase-deficient mice.";
RL   Gene Ther. 6:1898-1903(1999).
RN   [16] {ECO:0007744|PDB:4Y8W}
RP   X-RAY CRYSTALLOGRAPHY (2.64 ANGSTROMS) OF 29-494 IN COMPLEX WITH HEME AND
RP   PROGESTERONE, FUNCTION, COFACTOR, CATALYTIC ACTIVITY, AND
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=25855791; DOI=10.1074/jbc.m115.646307;
RA   Pallan P.S., Wang C., Lei L., Yoshimoto F.K., Auchus R.J., Waterman M.R.,
RA   Guengerich F.P., Egli M.;
RT   "Human Cytochrome P450 21A2, the major steroid 21-hydroxylase: structure of
RT   the enzyme-progesterone substrate complex and rate-limiting c-h bond
RT   cleavage.";
RL   J. Biol. Chem. 290:13128-13143(2015).
RN   [17]
RP   CHARACTERIZATION OF VARIANT AH3 LEU-281, AND MUTAGENESIS OF SER-268 AND
RP   CYS-428.
RX   PubMed=1864962; DOI=10.1172/jci115334;
RA   Wu D.-A., Chung B.-C.;
RT   "Mutations of P450c21 (steroid 21-hydroxylase) at Cys428, Val281, and
RT   Ser268 result in complete, partial, or no loss of enzymatic activity,
RT   respectively.";
RL   J. Clin. Invest. 88:519-523(1991).
RN   [18]
RP   REVIEW ON AH3 VARIANTS.
RA   Gunn S.K., Sherman L.D., Therrell B.L., Owerbach D.I.;
RT   "Molecular genetics of 21-hydroxylase deficient late-onset adrenal
RT   hyperplasia.";
RL   Semin. Reprod. Endocrinol. 11:347-352(1993).
RN   [19]
RP   REVIEW ON AH3 VARIANTS, AND GENE CONVERSION.
RX   PubMed=8081391; DOI=10.1002/humu.1380030408;
RA   White P.C., Tusie-Luna M.-T., New M.I., Speiser P.W.;
RT   "Mutations in steroid 21-hydroxylase (CYP21).";
RL   Hum. Mutat. 3:373-378(1994).
RN   [20]
RP   VARIANTS AH3 LEU-211 AND LEU-281.
RX   PubMed=3260007; DOI=10.1056/nejm198807073190104;
RA   Speiser P.W., New M.I., White P.C.;
RT   "Molecular genetic analysis of nonclassic steroid 21-hydroxylase deficiency
RT   associated with HLA-B14,DR1.";
RL   N. Engl. J. Med. 319:19-23(1988).
RN   [21]
RP   VARIANTS AH3 ASN-172 AND TRP-356, AND VARIANT LEU-9 INS.
RX   PubMed=2303461; DOI=10.1016/s0021-9258(19)39804-7;
RA   Chiou S.-H., Hu M.-C., Chung B.-C.;
RT   "A missense mutation at Ile172-->Asn or Arg356-->Trp causes steroid 21-
RT   hydroxylase deficiency.";
RL   J. Biol. Chem. 265:3549-3552(1990).
RN   [22]
RP   VARIANT AH3 ASN-172.
RX   PubMed=1937474; DOI=10.1007/bf00201731;
RA   Partanen J., Campbell R.D.;
RT   "Substitution of Ile-172 to Asn in the steroid 21-hydroxylase B (P450c21B)
RT   gene in a Finnish patient with the simple virilizing form of congenital
RT   adrenal hyperplasia.";
RL   Hum. Genet. 87:716-720(1991).
RN   [23]
RP   VARIANT AH3 LEU-30, AND VARIANT THR-268.
RX   PubMed=2072928; DOI=10.1210/mend-5-5-685;
RA   Tusie-Luna M.T., Speiser P.W., Dumic M., New M.I., White P.C.;
RT   "A mutation (Pro-30 to Leu) in CYP21 represents a potential nonclassic
RT   steroid 21-hydroxylase deficiency allele.";
RL   Mol. Endocrinol. 5:685-692(1991).
RN   [24]
RP   VARIANTS AH3 LEU-30; ASN-172; ASN-236; GLU-237; LYS-239; LEU-281 AND
RP   TRP-356.
RX   PubMed=1644925; DOI=10.1172/jci115897;
RA   Speiser P.W., Dupont J., Zhu D., Serrat J., Buegeleisen M.,
RA   Tusie-Luna M.-T., Lesser M., New M.I., White P.C.;
RT   "Disease expression and molecular genotype in congenital adrenal
RT   hyperplasia due to 21-hydroxylase deficiency.";
RL   J. Clin. Invest. 90:584-595(1992).
RN   [25]
RP   VARIANT AH3 SER-453.
RX   PubMed=1406699; DOI=10.1210/mend.6.8.1406699;
RA   Owerbach D., Sherman L., Ballard A.L., Azziz R.;
RT   "Pro-453 to Ser mutation in CYP21 is associated with nonclassic steroid 21-
RT   hydroxylase deficiency.";
RL   Mol. Endocrinol. 6:1211-1215(1992).
RN   [26]
RP   VARIANTS AH3 LEU-105; SER-291 AND SER-453.
RX   PubMed=1496017; DOI=10.1073/pnas.89.15.7232;
RA   Wedell A., Ritzen E.M., Haglund-Stengler B., Luthman H.;
RT   "Steroid 21-hydroxylase deficiency: three additional mutated alleles and
RT   establishment of phenotype-genotype relationships of common mutations.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:7232-7236(1992).
RN   [27]
RP   VARIANT AH3 PRO-483.
RX   PubMed=8478006; DOI=10.1007/bf00218263;
RA   Wedell A., Luthman H.;
RT   "Steroid 21-hydroxylase (P450c21): a new allele and spread of mutations
RT   through the pseudogene.";
RL   Hum. Genet. 91:236-240(1993).
RN   [28]
RP   VARIANTS AH3 ASN-172; ASN-236; LEU-281 AND PRO-483, AND VARIANT SER-493.
RX   PubMed=7749410; DOI=10.1002/humu.1380050205;
RA   Barbat B., Bogyo A., Raux-Demay M.-C., Kuttenn F., Boue J., Simon-Bouy B.,
RA   Serre J.-L., Boue A., Mornet E.;
RT   "Screening of CYP21 gene mutations in 129 French patients affected by
RT   steroid 21-hydroxylase deficiency.";
RL   Hum. Mutat. 5:126-130(1995).
RN   [29]
RP   VARIANT AH3 ASP-380.
RX   PubMed=9067760;
RX   DOI=10.1002/(sici)1098-1004(1997)9:2<181::aid-humu12>3.0.co;2-z;
RA   Kirby-Keyser L., Porter C.C., Donohoue P.A.;
RT   "E380D: a novel point mutation of CYP21 in an HLA-homozygous patient with
RT   salt-losing congenital adrenal hyperplasia due to 21-hydroxylase
RT   deficiency.";
RL   Hum. Mutat. 9:181-182(1997).
RN   [30]
RP   VARIANTS AH3 PRO-356 AND GLN-356.
RX   PubMed=9187661; DOI=10.1007/s004390050436;
RA   Lajic S., Levo A., Nikoshkov A., Lundberg Y., Partanen J., Wedell A.;
RT   "A cluster of missense mutations at Arg356 of human steroid 21-hydroxylase
RT   may impair redox partner interaction.";
RL   Hum. Genet. 99:704-709(1997).
RN   [31]
RP   VARIANTS AH3 LEU-105 AND SER-453.
RX   PubMed=8989258; DOI=10.1210/jcem.82.1.3678;
RA   Nikoshkov A., Lajic S., Holst M., Wedell A., Luthman H.;
RT   "Synergistic effect of partially inactivating mutations in steroid 21-
RT   hydroxylase deficiency.";
RL   J. Clin. Endocrinol. Metab. 82:194-199(1997).
RN   [32]
RP   VARIANTS AH3, AND VARIANTS.
RX   PubMed=9580109; DOI=10.1007/s004390050672;
RA   Ordonez-Sanchez M.L., Ramirez-Jimenez S., Lopez-Gutierrez A.U., Riba L.,
RA   Gamboa-Cardiel S., Cerrillo-Hinojosa M., Altamirano-Bustamante N.,
RA   Calzada-Leon R., Robles-Valdes C., Mendoza-Morfin F., Tusie-Luna M.T.;
RT   "Molecular genetic analysis of patients carrying steroid 21-hydroxylase
RT   deficiency in the Mexican population: identification of possible new
RT   mutations and high prevalence of apparent germ-line mutations.";
RL   Hum. Genet. 102:170-177(1998).
RN   [33]
RP   VARIANTS AH3 GLU-196 DEL; SER-291 AND PRO-483.
RX   PubMed=9497336; DOI=10.1074/jbc.273.11.6163;
RA   Nikoshkov A., Lajic S., Vlamis-Gardikas A., Tranebjaerg L., Holst M.,
RA   Wedell A., Luthman H.;
RT   "Naturally occurring mutants of human steroid 21-hydroxylase (P450c21)
RT   pinpoint residues important for enzyme activity and stability.";
RL   J. Biol. Chem. 273:6163-6165(1998).
RN   [34]
RP   VARIANT AH3 GLN-30, CHARACTERIZATION OF VARIANT AH3 GLN-30, SUBCELLULAR
RP   LOCATION, TOPOLOGY, AND DOMAIN.
RX   PubMed=10198222; DOI=10.1006/bbrc.1999.0482;
RA   Lajic S., Nikoshkov A., Holst M., Wedell A.;
RT   "Effects of missense mutations and deletions on membrane anchoring and
RT   enzyme function of human steroid 21-hydroxylase (P450c21).";
RL   Biochem. Biophys. Res. Commun. 257:384-390(1999).
RN   [35]
RP   VARIANTS AH3 LEU-30; VAL-90; ASN-172; ALA-178; LEU-281; CYS-291; HIS-354;
RP   TRP-356 AND SER-453.
RX   PubMed=10364682; DOI=10.1159/000022866;
RA   Lobato M.N., Ordonez-Sanchez M.L., Tusie-Luna M.T., Meseguer A.;
RT   "Mutation analysis in patients with congenital adrenal hyperplasia in the
RT   Spanish population: identification of putative novel steroid 21-hydroxylase
RT   deficiency alleles associated with the classic form of the disease.";
RL   Hum. Hered. 49:169-175(1999).
RN   [36]
RP   VARIANTS AH3 TYR-169; LEU-281 AND GLN-356.
RX   PubMed=10094562;
RX   DOI=10.1002/(sici)1098-1004(1999)13:2<172::aid-humu17>3.0.co;2-n;
RA   Witchel S.F., Smith R., Suda-Hartman M.;
RT   "Identification of CYP21 mutations, one novel, by single strand
RT   conformational polymorphism (SSCP) analysis.";
RL   Hum. Mutat. 13:172-172(1999).
RN   [37]
RP   VARIANTS AH3 LEU-30; GLU-64; ASN-172; ASN-236; LEU-281; SER-291; TRP-356
RP   AND VAL-362.
RX   PubMed=10408778;
RX   DOI=10.1002/(sici)1098-1004(1999)13:6<482::aid-humu8>3.0.co;2-0;
RA   Ohlsson G., Mueller J., Skakkebaek N.E., Schwartz M.;
RT   "Steroid 21-hydroxylase deficiency: mutational spectrum in Denmark, three
RT   novel mutations, and in vitro expression analysis.";
RL   Hum. Mutat. 13:482-486(1999).
RN   [38]
RP   VARIANTS AH3 LEU-30; ASN-172; ASN-236; GLU-237; LYS-239; LEU-281 AND
RP   TRP-356.
RX   PubMed=10408786;
RX   DOI=10.1002/(sici)1098-1004(1999)13:6<505::aid-humu16>3.0.co;2-0;
RA   Kapelari K., Ghanaati Z., Wollmann H., Ventz M., Ranke M.B., Kofler R.,
RA   Peters H.;
RT   "A rapid screening for steroid 21-hydroxylase mutations in patients with
RT   congenital adrenal hyperplasia.";
RL   Hum. Mutat. 13:505-505(1999).
RN   [39]
RP   VARIANTS AH3 LEU-281; TRP-356 AND SER-424.
RX   PubMed=10443693; DOI=10.1210/jcem.84.8.5937;
RA   Billerbeck A.E.C., Bachega T.A.S.S., Frazatto E.T., Nishi M.Y.,
RA   Goldberg A.C., Marin M.L.C., Madureira G., Monte O., Arnhold I.J.P.,
RA   Mendonca B.B.;
RT   "A novel missense mutation, GLY424SER, in Brazilian patients with 21-
RT   hydroxylase deficiency.";
RL   J. Clin. Endocrinol. Metab. 84:2870-2872(1999).
RN   [40]
RP   VARIANTS AH3 LEU-30; ASN-172; LEU-281; TRP-356 AND SER-493, AND VARIANT
RP   THR-268.
RX   PubMed=10496074; DOI=10.1007/s100380050167;
RA   Asanuma A., Ohura T., Ogawa E., Sato S., Igarashi Y., Matsubara Y.,
RA   Iinuma K.;
RT   "Molecular analysis of Japanese patients with steroid 21-hydroxylase
RT   deficiency.";
RL   J. Hum. Genet. 44:312-317(1999).
RN   [41]
RP   VARIANTS AH3 ASN-172 AND TRP-356.
RX   PubMed=10051010;
RA   Lako M., Ramsden S., Campbell R.D., Strachan T.;
RT   "Mutation screening in British 21-hydroxylase deficiency families and
RT   development of novel microsatellite based approaches to prenatal
RT   diagnosis.";
RL   J. Med. Genet. 36:119-124(1999).
RN   [42]
RP   VARIANTS AH3 LEU-281 AND SER-453, AND VARIANTS THR-268 AND SER-493.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions of
RT   human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [43]
RP   ERRATUM OF PUBMED:10391209.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
RN   [44]
RP   VARIANTS AH3 LEU-30; ASN-172; LEU-281; GLY-281; PHE-300; CYS-354; TRP-356
RP   AND SER-453.
RX   PubMed=10720040; DOI=10.1210/jcem.85.3.6441;
RA   Krone N., Braun A., Roscher A.A., Knorr D., Schwarz H.P.;
RT   "Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive
RT   genotyping in 155 unrelated, well defined patients from southern Germany.";
RL   J. Clin. Endocrinol. Metab. 85:1059-1065(2000).
RN   [45]
RP   VARIANTS AH3 LEU-30; ASN-172; PRO-261; TRP-356 AND PRO-483.
RX   PubMed=11598371; DOI=10.1159/000049992;
RA   Loke K.Y., Lee Y.S., Lee W.W.R., Poh L.K.S.;
RT   "Molecular analysis of CYP-21 mutations for congenital adrenal hyperplasia
RT   in Singapore.";
RL   Horm. Res. 55:179-184(2001).
RN   [46]
RP   VARIANTS AH3 LEU-30; ASN-172; LEU-281; MET-317; TRP-356; CYS-435 AND
RP   SER-453.
RX   PubMed=11232002; DOI=10.1210/jcem.86.1.7131;
RA   Deneux C., Tardy V., Dib A., Mornet E., Billaud L., Charron D., Morel Y.,
RA   Kuttenn F.;
RT   "Phenotype-genotype correlation in 56 women with nonclassical congenital
RT   adrenal hyperplasia due to 21-hydroxylase deficiency.";
RL   J. Clin. Endocrinol. Metab. 86:207-213(2001).
RN   [47]
RP   VARIANTS AH3 LEU-30; ASN-172; LEU-281; SER-291; TRP-356; SER-424; HIS-426;
RP   SER-453 AND PRO-483, AND CHARACTERIZATION OF VARIANT AH3 HIS-426.
RX   PubMed=11600539; DOI=10.1210/jcem.86.10.7898;
RA   Baumgartner-Parzer S.M., Schulze E., Waldhaeusl W., Pauschenwein S.,
RA   Rondot S., Nowotny P., Meyer K., Frisch H., Waldhauser F., Vierhapper H.;
RT   "Mutational spectrum of the steroid 21-hydroxylase gene in Austria:
RT   identification of a novel missense mutation.";
RL   J. Clin. Endocrinol. Metab. 86:4771-4775(2001).
RN   [48]
RP   VARIANT AH3 TRP-363.
RX   PubMed=11746135; DOI=10.1002/pd.167;
RA   Levo A., Partanen J.;
RT   "Novel mutations in the human CYP21 gene.";
RL   Prenat. Diagn. 21:885-889(2001).
RN   [49]
RP   VARIANTS AH3 LEU-30; ASN-172; LEU-281; LEU-283; TRP-356 AND SER-453.
RX   PubMed=12222711; DOI=10.1080/080352502760148595;
RA   Ezquieta B., Cueva E., Varela J., Oliver A., Fernandez J., Jariego C.;
RT   "Non-classical 21-hydroxylase deficiency in children: association of
RT   adrenocorticotropic hormone-stimulated 17-hydroxyprogesterone with the risk
RT   of compound heterozygosity with severe mutations.";
RL   Acta Paediatr. 91:892-898(2002).
RN   [50]
RP   VARIANTS HYPERANDROGENISM MET-304; SER-375 AND SER-453, AND
RP   CHARACTERIZATION OF VARIANTS HYPERANDROGENISM MET-304; SER-375 AND SER-453.
RX   PubMed=12050257; DOI=10.1210/jcem.87.6.8525;
RA   Lajic S., Clauin S., Robins T., Vexiau P., Blanche H.,
RA   Bellanne-Chantelot C., Wedell A.;
RT   "Novel mutations in CYP21 detected in individuals with hyperandrogenism.";
RL   J. Clin. Endocrinol. Metab. 87:2824-2829(2002).
RN   [51]
RP   VARIANTS AH3 CYS-408 AND SER-424.
RX   PubMed=12213891; DOI=10.1210/jc.2001-011939;
RA   Billerbeck A.E.C., Mendonca B.B., Pinto E.M., Madureira G., Arnhold I.J.P.,
RA   Bachega T.A.S.S.;
RT   "Three novel mutations in CYP21 gene in Brazilian patients with the
RT   classical form of 21-hydroxylase deficiency due to a founder effect.";
RL   J. Clin. Endocrinol. Metab. 87:4314-4317(2002).
RN   [52]
RP   VARIANTS AH3 THR-15; LEU-30; ASN-172; LEU-281 AND SER-453.
RX   PubMed=12887291; DOI=10.1530/eje.0.1490137;
RA   Dolzan V., Stopar-Obreza M., Zerjav-Tansek M., Breskvar K., Krzisnik C.,
RA   Battelino T.;
RT   "Mutational spectrum of congenital adrenal hyperplasia in Slovenian
RT   patients: a novel Ala15Thr mutation and Pro30Leu within a larger gene
RT   conversion associated with a severe form of the disease.";
RL   Eur. J. Endocrinol. 149:137-144(2003).
RN   [53]
RP   VARIANTS AH3 LEU-30; LEU-62; ASN-172; LEU-281; PRO-341; TRP-356; SER-453
RP   AND PRO-483.
RX   PubMed=12788866; DOI=10.1210/jc.2002-021433;
RA   Pinto G., Tardy V., Trivin C., Thalassinos C., Lortat-Jacob S.,
RA   Nihoul-Fekete C., Morel Y., Brauner R.;
RT   "Follow-up of 68 children with congenital adrenal hyperplasia due to 21-
RT   hydroxylase deficiency: relevance of genotype for management.";
RL   J. Clin. Endocrinol. Metab. 88:2624-2633(2003).
RN   [54]
RP   VARIANTS AH3 ASN-172; LEU-281; ARG-291; TYR-301; PRO-341; TRP-356 AND
RP   GLN-483.
RX   PubMed=12915679; DOI=10.1210/jc.2002-021681;
RA   Stikkelbroeck N.M., Hoefsloot L.H., de Wijs I.J., Otten B.J., Hermus A.R.,
RA   Sistermans E.A.;
RT   "CYP21 gene mutation analysis in 198 patients with 21-hydroxylase
RT   deficiency in The Netherlands: six novel mutations and a specific cluster
RT   of four mutations.";
RL   J. Clin. Endocrinol. Metab. 88:3852-3859(2003).
RN   [55]
RP   VARIANTS AH3 ASN-172; TRP-356 AND TRP-483.
RX   PubMed=14715874; DOI=10.1210/jc.2003-031056;
RA   Kharrat M., Tardy V., M'Rad R., Maazoul F., Jemaa L.B., Refai M., Morel Y.,
RA   Chaabouni H.;
RT   "Molecular genetic analysis of Tunisian patients with a classic form of 21-
RT   hydroxylase deficiency: identification of four novel mutations and high
RT   prevalence of Q318X mutation.";
RL   J. Clin. Endocrinol. Metab. 89:368-374(2004).
RN   [56]
RP   VARIANT AH3 HIS-124.
RX   PubMed=14676460; DOI=10.1159/000075587;
RA   Usui T., Nishisho K., Kaji M., Ikuno N., Yorifuji T., Yasuda T., Kuzuya H.,
RA   Shimatsu A.;
RT   "Three novel mutations in Japanese patients with 21-hydroxylase
RT   deficiency.";
RL   Horm. Res. 61:126-132(2004).
RN   [57]
RP   VARIANTS AH3 THR-15; LEU-30; LEU-281 AND SER-482, AND CHARACTERIZATION OF
RP   VARIANTS AH3 THR-15 AND SER-482.
RX   PubMed=15126570; DOI=10.1210/jc.2003-031630;
RA   Barbaro M., Lajic S., Baldazzi L., Balsamo A., Pirazzoli P., Cicognani A.,
RA   Wedell A., Cacciari E.;
RT   "Functional analysis of two recurrent amino acid substitutions in the CYP21
RT   gene from Italian patients with congenital adrenal hyperplasia.";
RL   J. Clin. Endocrinol. Metab. 89:2402-2407(2004).
RN   [58]
RP   VARIANTS AH3 LEU-30; ASN-172; ASN-236; GLU-237; LYS-239; LEU-281; SER-291;
RP   GLN-356; TRP-356; TYR-365; SER-453; LEU-479 AND PRO-483, AND VARIANT
RP   ARG-102.
RX   PubMed=15110320; DOI=10.1016/j.ymgme.2004.02.006;
RA   Zeng X., Witchel S.F., Dobrowolski S.F., Moulder P.V., Jarvik J.W.,
RA   Telmer C.A.;
RT   "Detection and assignment of CYP21 mutations using peptide mass signature
RT   genotyping.";
RL   Mol. Genet. Metab. 82:38-47(2004).
RN   [59]
RP   VARIANTS AH3 LEU-30; ASN-172 AND TRP-356.
RX   PubMed=16046588; DOI=10.1210/jc.2005-0379;
RA   Grigorescu Sido A., Weber M.M., Grigorescu Sido P., Clausmeyer S.,
RA   Heinrich U., Schulze E.;
RT   "21-Hydroxylase and 11beta-hydroxylase mutations in Romanian patients with
RT   classic congenital adrenal hyperplasia.";
RL   J. Clin. Endocrinol. Metab. 90:5769-5773(2005).
RN   [60]
RP   VARIANTS AH3 ARG-169; ARG-178; ARG-302 AND CYS-426, CHARACTERIZATION OF
RP   VARIANTS AH3 ARG-169; ARG-178; ARG-302; CYS-426 AND HIS-426, FUNCTION, AND
RP   CATALYTIC ACTIVITY.
RX   PubMed=16984992; DOI=10.1210/jc.2006-0777;
RA   Grischuk Y., Rubtsov P., Riepe F.G., Groetzinger J., Beljelarskaia S.,
RA   Prassolov V., Kalintchenko N., Semitcheva T., Peterkova V., Tiulpakov A.,
RA   Sippell W.G., Krone N.;
RT   "Four novel missense mutations in the CYP21A2 gene detected in Russian
RT   patients suffering from the classical form of congenital adrenal
RT   hyperplasia: identification, functional characterization, and structural
RT   analysis.";
RL   J. Clin. Endocrinol. Metab. 91:4976-4980(2006).
RN   [61]
RP   VARIANTS AH3 LEU-30; LEU-62; ASN-172; TRP-356 AND SER-453, AND
RP   CHARACTERIZATION OF VARIANTS AH3 LEU-62 AND SER-453.
RX   PubMed=18319307; DOI=10.1210/jc.2007-2701;
RA   Menassa R., Tardy V., Despert F., Bouvattier-Morel C., Brossier J.P.,
RA   Cartigny M., Morel Y.;
RT   "p.H62L, a rare mutation of the CYP21 gene identified in two forms of 21-
RT   hydroxylase deficiency.";
RL   J. Clin. Endocrinol. Metab. 93:1901-1908(2008).
RN   [62]
RP   VARIANTS AH3 ARG-56; LEU-62; ARG-107; PRO-142; ASN-172; TRP-356; CYS-408
RP   AND SER-453, AND CHARACTERIZATION OF VARIANTS AH3 ARG-56; LEU-62; ARG-107;
RP   PRO-142; CYS-408 AND SER-453.
RX   PubMed=18381579; DOI=10.1210/jc.2007-2594;
RA   Soardi F.C., Barbaro M., Lau I.F., Lemos-Marini S.H., Baptista M.T.,
RA   Guerra-Junior G., Wedell A., Lajic S., de Mello M.P.;
RT   "Inhibition of CYP21A2 enzyme activity caused by novel missense mutations
RT   identified in Brazilian and Scandinavian patients.";
RL   J. Clin. Endocrinol. Metab. 93:2416-2420(2008).
RN   [63]
RP   VARIANTS AH3 GLN-121 AND SER-453, AND CHARACTERIZATION OF VARIANT AH3
RP   GLN-121.
RX   PubMed=18445671; DOI=10.1210/jc.2007-2646;
RA   Riepe F.G., Hiort O., Grotzinger J., Sippell W.G., Krone N.,
RA   Holterhus P.M.;
RT   "Functional and structural consequences of a novel point mutation in the
RT   CYP21A2 gene causing congenital adrenal hyperplasia: potential relevance of
RT   helix C for P450 oxidoreductase-21-hydroxylase interaction.";
RL   J. Clin. Endocrinol. Metab. 93:2891-2895(2008).
RN   [64]
RP   VARIANTS AH3 THR-77; PRO-167; ASN-172; THR-230; LYS-233; LEU-281; SER-291;
RP   ASP-292; LYS-320; PRO-341; HIS-354; TRP-356; TRP-369; CYS-408; SER-424;
RP   HIS-426 AND SER-453, AND CHARACTERIZATION OF VARIANTS AH3 PRO-167; ASN-172;
RP   LEU-281; ASP-292; LYS-320; TRP-369 AND SER-424.
RX   PubMed=20080860; DOI=10.1210/jc.2009-1202;
RA   Tardy V., Menassa R., Sulmont V., Lienhardt-Roussie A., Lecointre C.,
RA   Brauner R., David M., Morel Y.;
RT   "Phenotype-genotype correlations of 13 rare CYP21A2 mutations detected in
RT   46 patients affected with 21-hydroxylase deficiency and in one carrier.";
RL   J. Clin. Endocrinol. Metab. 95:1288-1300(2010).
RN   [65]
RP   VARIANT AH3 PHE-198.
RX   PubMed=21169732; DOI=10.3275/7417;
RA   Niceta M., Bono M., Fabiano C., Pojero F., Niceta F., Sammarco P.,
RA   Corsello G., Garofalo P.;
RT   "A large view of CYP21 locus among Sicilians and other populations:
RT   identification of a novel CYP21A2 variant in Sicily.";
RL   J. Endocrinol. Invest. 34:847-854(2011).
RN   [66]
RP   VARIANTS AH3 HIS-191 AND ASN-282, CHARACTERIZATION OF VARIANTS AH3 HIS-191
RP   AND ASN-282, FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL
RP   PROPERTIES.
RX   PubMed=22014889; DOI=10.1016/j.metabol.2011.08.008;
RA   Concolino P., Mello E., Patrosso M.C., Penco S., Zuppi C., Capoluongo E.;
RT   "p.H282N and p.Y191H: 2 novel CYP21A2 mutations in Italian congenital
RT   adrenal hyperplasia patients.";
RL   Metabolism 61:519-524(2012).
RN   [67]
RP   VARIANTS AH3 MET-12; PHE-113; 389-GLN--ALA-391 DEL AND PRO-450, VARIANTS
RP   CYS-16; GLY-202; LEU-267 AND MET-450, CHARACTERIZATION OF VARIANTS AH3
RP   MET-12; PHE-113; 389-GLN--ALA-391 DEL; PRO-450 AND SER-482,
RP   CHARACTERIZATION OF VARIANTS CYS-16; GLY-202; LEU-267 AND MET-450,
RP   FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=27721825; DOI=10.1155/2016/4209670;
RA   de Paula Michelatto D., Karlsson L., Lusa A.L., Silva C.D., Oestberg L.J.,
RA   Persson B., Guerra-Junior G., de Lemos-Marini S.H., Barbaro M.,
RA   de Mello M.P., Lajic S.;
RT   "Functional and structural consequences of nine CYP21A2 mutations ranging
RT   from very mild to severe effects.";
RL   Int. J. Endocrinol. 2016:4209670-4209670(2016).
CC   -!- FUNCTION: A cytochrome P450 monooxygenase that plays a major role in
CC       adrenal steroidogenesis. Catalyzes the hydroxylation at C-21 of
CC       progesterone and 17alpha-hydroxyprogesterone to respectively form 11-
CC       deoxycorticosterone and 11-deoxycortisol, intermediate metabolites in
CC       the biosynthetic pathway of mineralocorticoids and glucocorticoids
CC       (PubMed:25855791, PubMed:10602386, PubMed:16984992, PubMed:22014889,
CC       PubMed:27721825). Mechanistically, uses molecular oxygen inserting one
CC       oxygen atom into a substrate, and reducing the second into a water
CC       molecule, with two electrons provided by NADPH via cytochrome P450
CC       reductase (CPR; NADPH-ferrihemoprotein reductase) (PubMed:25855791).
CC       {ECO:0000269|PubMed:10602386, ECO:0000269|PubMed:16984992,
CC       ECO:0000269|PubMed:22014889, ECO:0000269|PubMed:25855791,
CC       ECO:0000269|PubMed:27721825}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=O2 + progesterone + reduced [NADPH--hemoprotein reductase] =
CC         21-hydroxyprogesterone + H(+) + H2O + oxidized [NADPH--hemoprotein
CC         reductase]; Xref=Rhea:RHEA:50304, Rhea:RHEA-COMP:11964, Rhea:RHEA-
CC         COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:16973, ChEBI:CHEBI:17026, ChEBI:CHEBI:57618,
CC         ChEBI:CHEBI:58210; EC=1.14.14.16;
CC         Evidence={ECO:0000269|PubMed:16984992, ECO:0000269|PubMed:22014889,
CC         ECO:0000269|PubMed:25855791, ECO:0000269|PubMed:27721825};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50305;
CC         Evidence={ECO:0000305|PubMed:16984992, ECO:0000305|PubMed:22014889,
CC         ECO:0000305|PubMed:25855791, ECO:0000305|PubMed:27721825};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=17alpha-hydroxyprogesterone + O2 + reduced [NADPH--hemoprotein
CC         reductase] = 11-deoxycortisol + H(+) + H2O + oxidized
CC         [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:50308, Rhea:RHEA-
CC         COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:17252,
CC         ChEBI:CHEBI:28324, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210;
CC         EC=1.14.14.16; Evidence={ECO:0000269|PubMed:16984992,
CC         ECO:0000269|PubMed:22014889, ECO:0000269|PubMed:25855791,
CC         ECO:0000269|PubMed:27721825};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:50309;
CC         Evidence={ECO:0000305|PubMed:16984992, ECO:0000305|PubMed:22014889,
CC         ECO:0000305|PubMed:25855791, ECO:0000305|PubMed:27721825};
CC   -!- COFACTOR:
CC       Name=heme b; Xref=ChEBI:CHEBI:60344;
CC         Evidence={ECO:0000269|PubMed:25855791};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=1.59 uM for 17alpha-hydroxyprogesterone
CC         {ECO:0000269|PubMed:22014889};
CC         KM=12.5 uM for 17alpha-hydroxyprogesterone (at 37 degrees Celsius)
CC         {ECO:0000269|PubMed:27721825};
CC         KM=1.5 uM for 17alpha-hydroxyprogesterone
CC         {ECO:0000269|PubMed:25855791};
CC         KM=1.05 uM for progesterone {ECO:0000269|PubMed:22014889};
CC         KM=0.21 uM for progesterone {ECO:0000269|PubMed:25855791};
CC         Vmax=5.8 nmol/min/mg enzyme {ECO:0000269|PubMed:22014889};
CC         Vmax=0.5 nmol/min/mg enzyme (at 37 degrees Celsius)
CC         {ECO:0000269|PubMed:27721825};
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane; Peripheral
CC       membrane protein {ECO:0000269|PubMed:10198222}. Microsome membrane
CC       {ECO:0000269|PubMed:10198222}; Peripheral membrane protein
CC       {ECO:0000269|PubMed:10198222}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P08686-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P08686-2; Sequence=VSP_046264, VSP_046265;
CC   -!- DOMAIN: The leucine-rich hydrophobic amino acid N-terminal region
CC       probably helps to anchor the protein to the microsomal membrane.
CC       {ECO:0000269|PubMed:10198222}.
CC   -!- POLYMORPHISM: Seven non deleterious alleles are known: CYP21A2*1A,
CC       CYP21A2*1B, CYP21A2*2, CYP21A2*3, CYP21A2*4, CYP21A2*5 and CYP21A2*6.
CC       The sequence shown corresponds to allele CYP21A2*1B. Deleterious
CC       alleles are mostly generated by recombinations between CYP21A2 and the
CC       pseudogene CYP21A1P through gene conversion. This process consists of
CC       recombination events that either delete CYP21A2 or transfer deleterious
CC       mutations from CYP21A1P to CYP21A2.
CC   -!- DISEASE: Adrenal hyperplasia 3 (AH3) [MIM:201910]: A form of congenital
CC       adrenal hyperplasia, a common recessive disease due to defective
CC       synthesis of cortisol. Congenital adrenal hyperplasia is characterized
CC       by androgen excess leading to ambiguous genitalia in affected females,
CC       rapid somatic growth during childhood in both sexes with premature
CC       closure of the epiphyses and short adult stature. Four clinical types:
CC       'salt wasting' (SW, the most severe type), 'simple virilizing' (SV,
CC       less severely affected patients), with normal aldosterone biosynthesis,
CC       'non-classic form' or late-onset (NC or LOAH) and 'cryptic'
CC       (asymptomatic). {ECO:0000269|PubMed:10051010,
CC       ECO:0000269|PubMed:10094562, ECO:0000269|PubMed:10198222,
CC       ECO:0000269|PubMed:10364682, ECO:0000269|PubMed:10391209,
CC       ECO:0000269|PubMed:10408778, ECO:0000269|PubMed:10408786,
CC       ECO:0000269|PubMed:10443693, ECO:0000269|PubMed:10496074,
CC       ECO:0000269|PubMed:10720040, ECO:0000269|PubMed:11232002,
CC       ECO:0000269|PubMed:11598371, ECO:0000269|PubMed:11600539,
CC       ECO:0000269|PubMed:11746135, ECO:0000269|PubMed:12213891,
CC       ECO:0000269|PubMed:12222711, ECO:0000269|PubMed:12788866,
CC       ECO:0000269|PubMed:12887291, ECO:0000269|PubMed:12915679,
CC       ECO:0000269|PubMed:1406699, ECO:0000269|PubMed:1406709,
CC       ECO:0000269|PubMed:14676460, ECO:0000269|PubMed:14715874,
CC       ECO:0000269|PubMed:1496017, ECO:0000269|PubMed:15110320,
CC       ECO:0000269|PubMed:15126570, ECO:0000269|PubMed:16046588,
CC       ECO:0000269|PubMed:1644925, ECO:0000269|PubMed:16984992,
CC       ECO:0000269|PubMed:18319307, ECO:0000269|PubMed:18381579,
CC       ECO:0000269|PubMed:18445671, ECO:0000269|PubMed:1864962,
CC       ECO:0000269|PubMed:1937474, ECO:0000269|PubMed:20080860,
CC       ECO:0000269|PubMed:2072928, ECO:0000269|PubMed:21169732,
CC       ECO:0000269|PubMed:22014889, ECO:0000269|PubMed:2303461,
CC       ECO:0000269|PubMed:27721825, ECO:0000269|PubMed:3038528,
CC       ECO:0000269|PubMed:3257825, ECO:0000269|PubMed:3260007,
CC       ECO:0000269|PubMed:3267225, ECO:0000269|PubMed:3497399,
CC       ECO:0000269|PubMed:3871526, ECO:0000269|PubMed:7749410,
CC       ECO:0000269|PubMed:8478006, ECO:0000269|PubMed:8485582,
CC       ECO:0000269|PubMed:8989258, ECO:0000269|PubMed:9067760,
CC       ECO:0000269|PubMed:9187661, ECO:0000269|PubMed:9497336,
CC       ECO:0000269|PubMed:9580109}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the cytochrome P450 family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=PharmVar Pharmacogen Variation Consortium;
CC       Note=CYP21A2 alleles;
CC       URL="https://www.pharmvar.org/gene/CYP21A2";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M12792; AAB59440.1; -; Genomic_DNA.
DR   EMBL; M13936; AAA59695.1; -; Genomic_DNA.
DR   EMBL; M26856; AAA52064.1; -; Genomic_DNA.
DR   EMBL; X58906; CAA41709.1; -; Genomic_DNA.
DR   EMBL; GQ222286; ACT35412.1; -; Genomic_DNA.
DR   EMBL; GQ222296; ACT35422.1; -; Genomic_DNA.
DR   EMBL; GQ222301; ACT35427.1; -; Genomic_DNA.
DR   EMBL; AK054616; BAB70774.1; -; mRNA.
DR   EMBL; AL645922; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL662828; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL662849; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL844853; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL929593; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BX679671; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CR753845; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471081; EAX03570.1; -; Genomic_DNA.
DR   EMBL; CR936924; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC125182; AAI25183.1; -; mRNA.
DR   EMBL; K02771; AAA59706.1; -; Genomic_DNA.
DR   EMBL; M19711; AAA83248.1; -; Genomic_DNA.
DR   EMBL; M17252; AAA59985.1; -; mRNA.
DR   CCDS; CCDS47406.1; -. [P08686-2]
DR   PIR; A25446; O4HUC2.
DR   RefSeq; NP_000491.4; NM_000500.7.
DR   RefSeq; NP_001122062.3; NM_001128590.3.
DR   PDB; 4Y8W; X-ray; 2.64 A; A/B/C=29-494.
DR   PDBsum; 4Y8W; -.
DR   AlphaFoldDB; P08686; -.
DR   SMR; P08686; -.
DR   BioGRID; 107961; 20.
DR   IntAct; P08686; 2.
DR   STRING; 9606.ENSP00000408860; -.
DR   BindingDB; P08686; -.
DR   ChEMBL; CHEMBL2759; -.
DR   DrugBank; DB01026; Ketoconazole.
DR   DrugBank; DB05667; Levoketoconazole.
DR   DrugCentral; P08686; -.
DR   SwissLipids; SLP:000001618; -.
DR   iPTMnet; P08686; -.
DR   PhosphoSitePlus; P08686; -.
DR   BioMuta; CYP21A2; -.
DR   DMDM; 117275; -.
DR   MassIVE; P08686; -.
DR   PaxDb; P08686; -.
DR   PeptideAtlas; P08686; -.
DR   ProteomicsDB; 52155; -. [P08686-1]
DR   ProteomicsDB; 63894; -.
DR   Antibodypedia; 53182; 386 antibodies from 28 providers.
DR   DNASU; 1589; -.
DR   Ensembl; ENST00000383321.4; ENSP00000372811.4; ENSG00000206338.9.
DR   Ensembl; ENST00000434026.2; ENSP00000392321.2; ENSG00000232414.6.
DR   Ensembl; ENST00000435122.3; ENSP00000415043.2; ENSG00000231852.9.
DR   Ensembl; ENST00000436607.6; ENSP00000403721.2; ENSG00000235134.7. [P08686-1]
DR   Ensembl; ENST00000448314.6; ENSP00000398594.2; ENSG00000198457.13. [P08686-1]
DR   Ensembl; ENST00000452386.2; ENSP00000403230.2; ENSG00000233151.6.
DR   GeneID; 1589; -.
DR   KEGG; hsa:1589; -.
DR   UCSC; uc003nzf.3; human. [P08686-1]
DR   AGR; HGNC:2600; -.
DR   CTD; 1589; -.
DR   DisGeNET; 1589; -.
DR   GeneCards; CYP21A2; -.
DR   GeneReviews; CYP21A2; -.
DR   HGNC; HGNC:2600; CYP21A2.
DR   HPA; ENSG00000231852; Tissue enriched (adrenal).
DR   MalaCards; CYP21A2; -.
DR   MIM; 201910; phenotype.
DR   MIM; 613815; gene.
DR   neXtProt; NX_P08686; -.
DR   Orphanet; 315306; Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, salt wasting form.
DR   Orphanet; 315311; Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, simple virilizing form.
DR   Orphanet; 95698; NON RARE IN EUROPE: Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
DR   PharmGKB; PA27096; -.
DR   VEuPathDB; HostDB:ENSG00000231852; -.
DR   eggNOG; KOG0156; Eukaryota.
DR   InParanoid; P08686; -.
DR   OrthoDB; 2900138at2759; -.
DR   PhylomeDB; P08686; -.
DR   BioCyc; MetaCyc:HS09769-MON; -.
DR   BRENDA; 1.14.14.16; 2681.
DR   PathwayCommons; P08686; -.
DR   Reactome; R-HSA-193993; Mineralocorticoid biosynthesis.
DR   Reactome; R-HSA-194002; Glucocorticoid biosynthesis.
DR   Reactome; R-HSA-211976; Endogenous sterols.
DR   Reactome; R-HSA-5579021; Defective CYP21A2 causes AH3.
DR   SignaLink; P08686; -.
DR   SIGNOR; P08686; -.
DR   BioGRID-ORCS; 1589; 13 hits in 1141 CRISPR screens.
DR   ChiTaRS; CYP21A2; human.
DR   GeneWiki; 21-Hydroxylase; -.
DR   GenomeRNAi; 1589; -.
DR   Pharos; P08686; Tchem.
DR   PRO; PR:P08686; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; P08686; protein.
DR   Bgee; ENSG00000231852; Expressed in right adrenal gland and 90 other tissues.
DR   ExpressionAtlas; P08686; baseline and differential.
DR   Genevisible; P08686; HS.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0103069; F:17-hydroxyprogesterone 21-hydroxylase activity; IDA:UniProtKB.
DR   GO; GO:0020037; F:heme binding; IDA:UniProtKB.
DR   GO; GO:0005506; F:iron ion binding; IEA:InterPro.
DR   GO; GO:0106309; F:progesterone 21-hydroxylase activity; IDA:UniProtKB.
DR   GO; GO:0004509; F:steroid 21-monooxygenase activity; IBA:GO_Central.
DR   GO; GO:0005496; F:steroid binding; IEA:UniProtKB-KW.
DR   GO; GO:0008395; F:steroid hydroxylase activity; IMP:UniProtKB.
DR   GO; GO:0006704; P:glucocorticoid biosynthetic process; IBA:GO_Central.
DR   GO; GO:0006705; P:mineralocorticoid biosynthetic process; TAS:Reactome.
DR   GO; GO:0006694; P:steroid biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0008202; P:steroid metabolic process; IMP:UniProtKB.
DR   GO; GO:0016125; P:sterol metabolic process; TAS:Reactome.
DR   CDD; cd20674; CYP21; 1.
DR   Gene3D; 1.10.630.10; Cytochrome P450; 1.
DR   InterPro; IPR001128; Cyt_P450.
DR   InterPro; IPR017972; Cyt_P450_CS.
DR   InterPro; IPR002401; Cyt_P450_E_grp-I.
DR   InterPro; IPR036396; Cyt_P450_sf.
DR   PANTHER; PTHR24289; STEROID 17-ALPHA-HYDROXYLASE/17,20 LYASE; 1.
DR   PANTHER; PTHR24289:SF13; STEROID 17-ALPHA-HYDROXYLASE/17,20 LYASE; 1.
DR   Pfam; PF00067; p450; 1.
DR   PRINTS; PR00463; EP450I.
DR   PRINTS; PR00385; P450.
DR   SUPFAM; SSF48264; Cytochrome P450; 1.
DR   PROSITE; PS00086; CYTOCHROME_P450; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Congenital adrenal hyperplasia;
KW   Disease variant; Endoplasmic reticulum; Heme; Iron; Lipid metabolism;
KW   Lipid-binding; Membrane; Metal-binding; Microsome; Monooxygenase;
KW   Oxidoreductase; Reference proteome; Steroid-binding; Steroidogenesis.
FT   CHAIN           1..494
FT                   /note="Steroid 21-hydroxylase"
FT                   /id="PRO_0000051976"
FT   BINDING         91
FT                   /ligand="heme b"
FT                   /ligand_id="ChEBI:CHEBI:60344"
FT                   /evidence="ECO:0000269|PubMed:25855791,
FT                   ECO:0007744|PDB:4Y8W"
FT   BINDING         120
FT                   /ligand="heme b"
FT                   /ligand_id="ChEBI:CHEBI:60344"
FT                   /evidence="ECO:0000269|PubMed:25855791,
FT                   ECO:0007744|PDB:4Y8W"
FT   BINDING         233
FT                   /ligand="17alpha-hydroxyprogesterone"
FT                   /ligand_id="ChEBI:CHEBI:17252"
FT                   /evidence="ECO:0000250|UniProtKB:P00191"
FT   BINDING         233
FT                   /ligand="progesterone"
FT                   /ligand_id="ChEBI:CHEBI:17026"
FT                   /evidence="ECO:0000269|PubMed:25855791,
FT                   ECO:0007744|PDB:4Y8W"
FT   BINDING         365
FT                   /ligand="heme b"
FT                   /ligand_id="ChEBI:CHEBI:60344"
FT                   /evidence="ECO:0000269|PubMed:25855791,
FT                   ECO:0007744|PDB:4Y8W"
FT   BINDING         426
FT                   /ligand="heme b"
FT                   /ligand_id="ChEBI:CHEBI:60344"
FT                   /evidence="ECO:0000269|PubMed:25855791,
FT                   ECO:0007744|PDB:4Y8W"
FT   BINDING         428
FT                   /ligand="heme b"
FT                   /ligand_id="ChEBI:CHEBI:60344"
FT                   /ligand_part="Fe"
FT                   /ligand_part_id="ChEBI:CHEBI:18248"
FT                   /note="axial binding residue"
FT                   /evidence="ECO:0000269|PubMed:25855791,
FT                   ECO:0007744|PDB:4Y8W"
FT   VAR_SEQ         6
FT                   /note="L -> LL (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_046264"
FT   VAR_SEQ         68..102
FT                   /note="VVVLNSKRTIEEAMVKKWADFAGRPEPLTYKLVSK -> KLVSR (in
FT                   isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_046265"
FT   VARIANT         9
FT                   /note="L -> LL (in allele CYP21A2*2)"
FT                   /evidence="ECO:0000269|PubMed:1406709,
FT                   ECO:0000269|PubMed:2303461, ECO:0000269|PubMed:3038528,
FT                   ECO:0000269|PubMed:3267225"
FT                   /id="VAR_018363"
FT   VARIANT         12
FT                   /note="L -> M (in AH3; non-classic form; unknown
FT                   pathological significance; no effect on steroid
FT                   21-monooxygenase activity)"
FT                   /evidence="ECO:0000269|PubMed:27721825"
FT                   /id="VAR_077582"
FT   VARIANT         15
FT                   /note="A -> T (in AH3; salt wasting form; unknown
FT                   pathological significance; no significant difference in
FT                   steroid 21-monooxygenase activity; dbSNP:rs63749090)"
FT                   /evidence="ECO:0000269|PubMed:12887291,
FT                   ECO:0000269|PubMed:15126570"
FT                   /id="VAR_026059"
FT   VARIANT         16
FT                   /note="R -> C (decreased steroid 21-monooxygenase activity;
FT                   dbSNP:rs757608533)"
FT                   /evidence="ECO:0000269|PubMed:27721825"
FT                   /id="VAR_077583"
FT   VARIANT         30
FT                   /note="P -> L (in AH3; non-classic form; 10% of non-classic
FT                   AH3 Texan patients; 50% steroid 21-monooxygenase activity;
FT                   dbSNP:rs9378251)"
FT                   /evidence="ECO:0000269|PubMed:10364682,
FT                   ECO:0000269|PubMed:10408778, ECO:0000269|PubMed:10408786,
FT                   ECO:0000269|PubMed:10496074, ECO:0000269|PubMed:10720040,
FT                   ECO:0000269|PubMed:11232002, ECO:0000269|PubMed:11598371,
FT                   ECO:0000269|PubMed:11600539, ECO:0000269|PubMed:12222711,
FT                   ECO:0000269|PubMed:12788866, ECO:0000269|PubMed:12887291,
FT                   ECO:0000269|PubMed:15110320, ECO:0000269|PubMed:15126570,
FT                   ECO:0000269|PubMed:16046588, ECO:0000269|PubMed:1644925,
FT                   ECO:0000269|PubMed:18319307, ECO:0000269|PubMed:2072928"
FT                   /id="VAR_001281"
FT   VARIANT         30
FT                   /note="P -> Q (in AH3; does not affect membrane binding;
FT                   enzyme function abolished)"
FT                   /evidence="ECO:0000269|PubMed:10198222"
FT                   /id="VAR_026060"
FT   VARIANT         56
FT                   /note="G -> R (in AH3; loss of activity;
FT                   dbSNP:rs1413433421)"
FT                   /evidence="ECO:0000269|PubMed:18381579"
FT                   /id="VAR_065668"
FT   VARIANT         62
FT                   /note="H -> L (in AH3; non-classic form; simple virilizing
FT                   form when associated with a second mild mutation such as
FT                   S-453 or L-30; activity is significantly reduced in
FT                   association with S-453; dbSNP:rs9378252)"
FT                   /evidence="ECO:0000269|PubMed:12788866,
FT                   ECO:0000269|PubMed:18319307, ECO:0000269|PubMed:18381579"
FT                   /id="VAR_018364"
FT   VARIANT         64
FT                   /note="G -> E (in AH3; no activity)"
FT                   /evidence="ECO:0000269|PubMed:10408778"
FT                   /id="VAR_007923"
FT   VARIANT         77
FT                   /note="I -> T (in AH3; simple virilizing form;
FT                   dbSNP:rs1333278223)"
FT                   /evidence="ECO:0000269|PubMed:20080860"
FT                   /id="VAR_065669"
FT   VARIANT         90
FT                   /note="G -> V (in AH3)"
FT                   /evidence="ECO:0000269|PubMed:10364682"
FT                   /id="VAR_026061"
FT   VARIANT         98
FT                   /note="K -> R (in dbSNP:rs1268071078)"
FT                   /id="VAR_001282"
FT   VARIANT         102
FT                   /note="K -> R (in allele CYP21A2*3; dbSNP:rs6474)"
FT                   /evidence="ECO:0000269|PubMed:1406709,
FT                   ECO:0000269|PubMed:15110320, ECO:0000269|PubMed:3038528"
FT                   /id="VAR_001283"
FT   VARIANT         105
FT                   /note="P -> L (in AH3; dbSNP:rs550051210)"
FT                   /evidence="ECO:0000269|PubMed:1496017,
FT                   ECO:0000269|PubMed:8989258"
FT                   /id="VAR_001284"
FT   VARIANT         107
FT                   /note="L -> R (in AH3; loss of activity;
FT                   dbSNP:rs957886272)"
FT                   /evidence="ECO:0000269|PubMed:18381579"
FT                   /id="VAR_065670"
FT   VARIANT         113
FT                   /note="S -> F (in AH3; non-classic form; loss of steroid
FT                   21-monooxygenase activity; dbSNP:rs1296268275)"
FT                   /evidence="ECO:0000269|PubMed:27721825"
FT                   /id="VAR_077584"
FT   VARIANT         121
FT                   /note="K -> Q (in AH3; non-classic form; reduced activity;
FT                   decreased affinity for 17-hydroxyprogesterone and
FT                   progesterone; dbSNP:rs547552654)"
FT                   /evidence="ECO:0000269|PubMed:18445671"
FT                   /id="VAR_065671"
FT   VARIANT         124
FT                   /note="R -> H (in AH3; dbSNP:rs72552750)"
FT                   /evidence="ECO:0000269|PubMed:14676460"
FT                   /id="VAR_026062"
FT   VARIANT         142
FT                   /note="L -> P (in AH3; loss of activity;
FT                   dbSNP:rs755020999)"
FT                   /evidence="ECO:0000269|PubMed:18381579"
FT                   /id="VAR_065672"
FT   VARIANT         167
FT                   /note="L -> P (in AH3; salt wasting form; loss of
FT                   activity)"
FT                   /evidence="ECO:0000269|PubMed:20080860"
FT                   /id="VAR_065673"
FT   VARIANT         169
FT                   /note="C -> R (in AH3; loss of hydroxylase activity toward
FT                   17-hydroxyprogesterone and progesterone)"
FT                   /evidence="ECO:0000269|PubMed:16984992"
FT                   /id="VAR_075372"
FT   VARIANT         169
FT                   /note="C -> Y (in AH3)"
FT                   /evidence="ECO:0000269|PubMed:10094562"
FT                   /id="VAR_001285"
FT   VARIANT         172
FT                   /note="I -> N (in AH3; simple virilizing form; 1-4%
FT                   activity; dbSNP:rs6475)"
FT                   /evidence="ECO:0000269|PubMed:10051010,
FT                   ECO:0000269|PubMed:10364682, ECO:0000269|PubMed:10408778,
FT                   ECO:0000269|PubMed:10408786, ECO:0000269|PubMed:10496074,
FT                   ECO:0000269|PubMed:10720040, ECO:0000269|PubMed:11232002,
FT                   ECO:0000269|PubMed:11598371, ECO:0000269|PubMed:11600539,
FT                   ECO:0000269|PubMed:12222711, ECO:0000269|PubMed:12788866,
FT                   ECO:0000269|PubMed:12887291, ECO:0000269|PubMed:12915679,
FT                   ECO:0000269|PubMed:14715874, ECO:0000269|PubMed:15110320,
FT                   ECO:0000269|PubMed:16046588, ECO:0000269|PubMed:1644925,
FT                   ECO:0000269|PubMed:18319307, ECO:0000269|PubMed:18381579,
FT                   ECO:0000269|PubMed:1937474, ECO:0000269|PubMed:20080860,
FT                   ECO:0000269|PubMed:2303461, ECO:0000269|PubMed:3257825,
FT                   ECO:0000269|PubMed:3871526, ECO:0000269|PubMed:7749410,
FT                   ECO:0000269|PubMed:8485582"
FT                   /id="VAR_001286"
FT   VARIANT         178
FT                   /note="G -> A (in AH3; dbSNP:rs72552751)"
FT                   /evidence="ECO:0000269|PubMed:10364682"
FT                   /id="VAR_026063"
FT   VARIANT         178
FT                   /note="G -> R (in AH3; loss of enzymatic activity toward
FT                   17-hydroxyprogesterone and progesterone;
FT                   dbSNP:rs772317717)"
FT                   /evidence="ECO:0000269|PubMed:16984992"
FT                   /id="VAR_075373"
FT   VARIANT         183
FT                   /note="D -> E (in allele CYP21A2*4; dbSNP:rs397515531)"
FT                   /id="VAR_001287"
FT   VARIANT         191
FT                   /note="Y -> H (in AH3; exhibits low enzymatic activity
FT                   toward 17-hydroxyprogesterone and progesterone)"
FT                   /evidence="ECO:0000269|PubMed:22014889"
FT                   /id="VAR_075374"
FT   VARIANT         196
FT                   /note="Missing (in AH3; moderate)"
FT                   /evidence="ECO:0000269|PubMed:9497336"
FT                   /id="VAR_008688"
FT   VARIANT         198
FT                   /note="L -> F (in AH3; dbSNP:rs143240527)"
FT                   /evidence="ECO:0000269|PubMed:21169732"
FT                   /id="VAR_075375"
FT   VARIANT         202
FT                   /note="S -> G (decreased steroid 21-monooxygenase activity;
FT                   dbSNP:rs372964292)"
FT                   /evidence="ECO:0000269|PubMed:27721825"
FT                   /id="VAR_077585"
FT   VARIANT         211
FT                   /note="V -> L (in AH3; non-classic form; pathogenicity
FT                   uncertain)"
FT                   /evidence="ECO:0000269|PubMed:3260007"
FT                   /id="VAR_026064"
FT   VARIANT         230
FT                   /note="I -> T (in AH3)"
FT                   /evidence="ECO:0000269|PubMed:20080860"
FT                   /id="VAR_065674"
FT   VARIANT         233
FT                   /note="R -> K (in AH3)"
FT                   /evidence="ECO:0000269|PubMed:20080860"
FT                   /id="VAR_065675"
FT   VARIANT         236
FT                   /note="I -> N (in AH3; salt wasting form;
FT                   dbSNP:rs111647200)"
FT                   /evidence="ECO:0000269|PubMed:10408778,
FT                   ECO:0000269|PubMed:10408786, ECO:0000269|PubMed:15110320,
FT                   ECO:0000269|PubMed:1644925, ECO:0000269|PubMed:7749410"
FT                   /id="VAR_001288"
FT   VARIANT         237
FT                   /note="V -> E (in AH3; salt wasting form;
FT                   dbSNP:rs12530380)"
FT                   /evidence="ECO:0000269|PubMed:10408786,
FT                   ECO:0000269|PubMed:15110320, ECO:0000269|PubMed:1644925"
FT                   /id="VAR_001289"
FT   VARIANT         239
FT                   /note="M -> K (in AH3; salt wasting form; dbSNP:rs6476)"
FT                   /evidence="ECO:0000269|PubMed:10408786,
FT                   ECO:0000269|PubMed:15110320, ECO:0000269|PubMed:1644925"
FT                   /id="VAR_001290"
FT   VARIANT         261
FT                   /note="L -> P (in AH3; dbSNP:rs750337015)"
FT                   /evidence="ECO:0000269|PubMed:11598371"
FT                   /id="VAR_026065"
FT   VARIANT         267
FT                   /note="P -> L (decreased steroid 21-monooxygenase activity;
FT                   dbSNP:rs61732108 and dbSNP:rs142028935)"
FT                   /evidence="ECO:0000269|PubMed:27721825"
FT                   /id="VAR_077586"
FT   VARIANT         268
FT                   /note="S -> T (in allele CYP21A2*5; dbSNP:rs6472)"
FT                   /evidence="ECO:0000269|PubMed:10391209,
FT                   ECO:0000269|PubMed:10496074, ECO:0000269|PubMed:2072928,
FT                   ECO:0000269|PubMed:3038528"
FT                   /id="VAR_001291"
FT   VARIANT         281
FT                   /note="V -> G (in AH3; salt wasting form)"
FT                   /evidence="ECO:0000269|PubMed:10720040"
FT                   /id="VAR_026066"
FT   VARIANT         281
FT                   /note="V -> L (in AH3; non-classic form; 50% activity; most
FT                   common variant; normal KM but 20% reduced Vmax;
FT                   dbSNP:rs6471)"
FT                   /evidence="ECO:0000269|PubMed:10094562,
FT                   ECO:0000269|PubMed:10364682, ECO:0000269|PubMed:10391209,
FT                   ECO:0000269|PubMed:10408778, ECO:0000269|PubMed:10408786,
FT                   ECO:0000269|PubMed:10443693, ECO:0000269|PubMed:10496074,
FT                   ECO:0000269|PubMed:10720040, ECO:0000269|PubMed:11232002,
FT                   ECO:0000269|PubMed:11600539, ECO:0000269|PubMed:12222711,
FT                   ECO:0000269|PubMed:12788866, ECO:0000269|PubMed:12887291,
FT                   ECO:0000269|PubMed:12915679, ECO:0000269|PubMed:15110320,
FT                   ECO:0000269|PubMed:15126570, ECO:0000269|PubMed:1644925,
FT                   ECO:0000269|PubMed:1864962, ECO:0000269|PubMed:20080860,
FT                   ECO:0000269|PubMed:3260007, ECO:0000269|PubMed:3267225,
FT                   ECO:0000269|PubMed:3497399, ECO:0000269|PubMed:7749410"
FT                   /id="VAR_001292"
FT   VARIANT         282
FT                   /note="H -> N (in AH3; exhibits low enzymatic activity
FT                   toward 17-hydroxyprogesterone and progesterone)"
FT                   /evidence="ECO:0000269|PubMed:22014889"
FT                   /id="VAR_075376"
FT   VARIANT         283
FT                   /note="M -> L (in AH3)"
FT                   /evidence="ECO:0000269|PubMed:12222711"
FT                   /id="VAR_026067"
FT   VARIANT         291
FT                   /note="G -> C (in AH3)"
FT                   /evidence="ECO:0000269|PubMed:10364682"
FT                   /id="VAR_026068"
FT   VARIANT         291
FT                   /note="G -> R (in AH3; dbSNP:rs201552310)"
FT                   /evidence="ECO:0000269|PubMed:12915679"
FT                   /id="VAR_018365"
FT   VARIANT         291
FT                   /note="G -> S (in AH3; salt wasting form; less then 1%
FT                   activity; dbSNP:rs201552310)"
FT                   /evidence="ECO:0000269|PubMed:10408778,
FT                   ECO:0000269|PubMed:11600539, ECO:0000269|PubMed:1496017,
FT                   ECO:0000269|PubMed:15110320, ECO:0000269|PubMed:20080860,
FT                   ECO:0000269|PubMed:9497336"
FT                   /id="VAR_001293"
FT   VARIANT         292
FT                   /note="G -> D (in AH3; salt wasting form; less then 1%
FT                   activity)"
FT                   /evidence="ECO:0000269|PubMed:20080860"
FT                   /id="VAR_065676"
FT   VARIANT         300
FT                   /note="L -> F (in AH3; salt wasting form;
FT                   dbSNP:rs765001985)"
FT                   /evidence="ECO:0000269|PubMed:10720040"
FT                   /id="VAR_026069"
FT   VARIANT         301
FT                   /note="S -> Y (in AH3)"
FT                   /evidence="ECO:0000269|PubMed:12915679"
FT                   /id="VAR_018366"
FT   VARIANT         302
FT                   /note="W -> R (in AH3; loss of enzymatic activity toward
FT                   17-hydroxyprogesterone and progesterone)"
FT                   /evidence="ECO:0000269|PubMed:16984992"
FT                   /id="VAR_075377"
FT   VARIANT         304
FT                   /note="V -> M (in hyperandrogenism; due to 21-hydroxylase
FT                   deficiency; non-classic type; residual activity of 46% for
FT                   conversion of 17-hydroxyprogesterone and 26% for conversion
FT                   of progesterone compared with the normal enzyme;
FT                   dbSNP:rs151344505)"
FT                   /evidence="ECO:0000269|PubMed:12050257"
FT                   /id="VAR_026070"
FT   VARIANT         317
FT                   /note="L -> M (in AH3)"
FT                   /evidence="ECO:0000269|PubMed:11232002"
FT                   /id="VAR_026071"
FT   VARIANT         320
FT                   /note="E -> K (in AH3; simple virilizing form; 4%
FT                   activity)"
FT                   /evidence="ECO:0000269|PubMed:20080860"
FT                   /id="VAR_065677"
FT   VARIANT         339
FT                   /note="R -> H (in AH3; non-classic form; 50% activity;
FT                   dbSNP:rs72552754)"
FT                   /evidence="ECO:0000269|PubMed:1406709"
FT                   /id="VAR_001294"
FT   VARIANT         341
FT                   /note="R -> P (in AH3; simple virilizing form;
FT                   dbSNP:rs747079101)"
FT                   /evidence="ECO:0000269|PubMed:12788866,
FT                   ECO:0000269|PubMed:12915679, ECO:0000269|PubMed:20080860"
FT                   /id="VAR_018367"
FT   VARIANT         341
FT                   /note="R -> W (in AH3; non-classic form; mild;
FT                   dbSNP:rs72552755)"
FT                   /id="VAR_001295"
FT   VARIANT         354
FT                   /note="R -> C (in AH3; salt wasting form;
FT                   dbSNP:rs772900496)"
FT                   /evidence="ECO:0000269|PubMed:10720040"
FT                   /id="VAR_026072"
FT   VARIANT         354
FT                   /note="R -> H (in AH3; salt wasting form;
FT                   dbSNP:rs760216630)"
FT                   /evidence="ECO:0000269|PubMed:10364682,
FT                   ECO:0000269|PubMed:20080860"
FT                   /id="VAR_026073"
FT   VARIANT         356
FT                   /note="R -> P (in AH3; salt wasting form; 0.15% activity)"
FT                   /evidence="ECO:0000269|PubMed:9187661"
FT                   /id="VAR_001296"
FT   VARIANT         356
FT                   /note="R -> Q (in AH3; simple virilizing form; mild; 0.65%
FT                   activity; dbSNP:rs574370139)"
FT                   /evidence="ECO:0000269|PubMed:10094562,
FT                   ECO:0000269|PubMed:15110320, ECO:0000269|PubMed:9187661"
FT                   /id="VAR_001297"
FT   VARIANT         356
FT                   /note="R -> W (in AH3; salt wasting form; dbSNP:rs7769409)"
FT                   /evidence="ECO:0000269|PubMed:10051010,
FT                   ECO:0000269|PubMed:10364682, ECO:0000269|PubMed:10408778,
FT                   ECO:0000269|PubMed:10408786, ECO:0000269|PubMed:10443693,
FT                   ECO:0000269|PubMed:10496074, ECO:0000269|PubMed:10720040,
FT                   ECO:0000269|PubMed:11232002, ECO:0000269|PubMed:11598371,
FT                   ECO:0000269|PubMed:11600539, ECO:0000269|PubMed:12222711,
FT                   ECO:0000269|PubMed:12788866, ECO:0000269|PubMed:12915679,
FT                   ECO:0000269|PubMed:14715874, ECO:0000269|PubMed:15110320,
FT                   ECO:0000269|PubMed:16046588, ECO:0000269|PubMed:1644925,
FT                   ECO:0000269|PubMed:18319307, ECO:0000269|PubMed:18381579,
FT                   ECO:0000269|PubMed:20080860, ECO:0000269|PubMed:2303461"
FT                   /id="VAR_001298"
FT   VARIANT         362
FT                   /note="A -> V (in AH3; no activity)"
FT                   /evidence="ECO:0000269|PubMed:10408778"
FT                   /id="VAR_007924"
FT   VARIANT         363
FT                   /note="L -> W (in AH3)"
FT                   /evidence="ECO:0000269|PubMed:11746135"
FT                   /id="VAR_026074"
FT   VARIANT         365
FT                   /note="H -> Y (in AH3; dbSNP:rs1330554738)"
FT                   /evidence="ECO:0000269|PubMed:15110320"
FT                   /id="VAR_026075"
FT   VARIANT         369
FT                   /note="R -> W (in AH3; dbSNP:rs781074931)"
FT                   /evidence="ECO:0000269|PubMed:20080860"
FT                   /id="VAR_065678"
FT   VARIANT         375
FT                   /note="G -> S (in hyperandrogenism; due to 21-hydroxylase
FT                   deficiency; almost completely abolished enzyme activity;
FT                   dbSNP:rs151344506)"
FT                   /evidence="ECO:0000269|PubMed:12050257"
FT                   /id="VAR_026076"
FT   VARIANT         380
FT                   /note="E -> D (in AH3; salt wasting form;
FT                   dbSNP:rs72552756)"
FT                   /evidence="ECO:0000269|PubMed:9067760"
FT                   /id="VAR_001299"
FT   VARIANT         389..391
FT                   /note="Missing (in AH3; salt wasting form; loss of steroid
FT                   21-monooxygenase activity)"
FT                   /evidence="ECO:0000269|PubMed:27721825"
FT                   /id="VAR_077587"
FT   VARIANT         408
FT                   /note="R -> C (in AH3; very low residual activity;
FT                   dbSNP:rs72552757)"
FT                   /evidence="ECO:0000269|PubMed:12213891,
FT                   ECO:0000269|PubMed:18381579, ECO:0000269|PubMed:20080860"
FT                   /id="VAR_026077"
FT   VARIANT         424
FT                   /note="G -> S (in AH3; very low activity;
FT                   dbSNP:rs72552758)"
FT                   /evidence="ECO:0000269|PubMed:10443693,
FT                   ECO:0000269|PubMed:11600539, ECO:0000269|PubMed:12213891,
FT                   ECO:0000269|PubMed:20080860"
FT                   /id="VAR_026078"
FT   VARIANT         426
FT                   /note="R -> C (in AH3; loss of enzymatic activity toward
FT                   17-hydroxyprogesterone and progesterone;
FT                   dbSNP:rs1370167869)"
FT                   /evidence="ECO:0000269|PubMed:16984992"
FT                   /id="VAR_075378"
FT   VARIANT         426
FT                   /note="R -> H (in AH3; loss of enzymatic activity toward
FT                   17-hydroxyprogesterone; dbSNP:rs151344504)"
FT                   /evidence="ECO:0000269|PubMed:11600539,
FT                   ECO:0000269|PubMed:16984992, ECO:0000269|PubMed:20080860"
FT                   /id="VAR_026079"
FT   VARIANT         435
FT                   /note="R -> C (in AH3; dbSNP:rs767333157)"
FT                   /evidence="ECO:0000269|PubMed:11232002"
FT                   /id="VAR_026080"
FT   VARIANT         450
FT                   /note="T -> M (decreased steroid 21-monooxygenase activity;
FT                   dbSNP:rs1319651744)"
FT                   /evidence="ECO:0000269|PubMed:27721825"
FT                   /id="VAR_077588"
FT   VARIANT         450
FT                   /note="T -> P (in AH3; salt wasting form; loss of steroid
FT                   21-monooxygenase activity)"
FT                   /evidence="ECO:0000269|PubMed:27721825"
FT                   /id="VAR_077589"
FT   VARIANT         453
FT                   /note="P -> S (in AH3; non-classic form; simple virilizing
FT                   form when associated with L-62; 50% of activity; almost
FT                   completely abolished enzyme activity when associated with
FT                   S-375; dbSNP:rs6445)"
FT                   /evidence="ECO:0000269|PubMed:10364682,
FT                   ECO:0000269|PubMed:10391209, ECO:0000269|PubMed:10720040,
FT                   ECO:0000269|PubMed:11232002, ECO:0000269|PubMed:11600539,
FT                   ECO:0000269|PubMed:12050257, ECO:0000269|PubMed:12222711,
FT                   ECO:0000269|PubMed:12788866, ECO:0000269|PubMed:12887291,
FT                   ECO:0000269|PubMed:1406699, ECO:0000269|PubMed:1406709,
FT                   ECO:0000269|PubMed:1496017, ECO:0000269|PubMed:15110320,
FT                   ECO:0000269|PubMed:18319307, ECO:0000269|PubMed:18381579,
FT                   ECO:0000269|PubMed:18445671, ECO:0000269|PubMed:20080860,
FT                   ECO:0000269|PubMed:8989258"
FT                   /id="VAR_001300"
FT   VARIANT         479
FT                   /note="R -> L (in AH3; dbSNP:rs184649564)"
FT                   /evidence="ECO:0000269|PubMed:15110320"
FT                   /id="VAR_026081"
FT   VARIANT         482
FT                   /note="P -> S (in AH3; reduced enzyme activity to 70% of
FT                   normal; dbSNP:rs776989258)"
FT                   /evidence="ECO:0000269|PubMed:15126570,
FT                   ECO:0000269|PubMed:27721825"
FT                   /id="VAR_026082"
FT   VARIANT         483
FT                   /note="R -> P (in AH3; moderate; 1-2% of activity;
FT                   dbSNP:rs200005406)"
FT                   /evidence="ECO:0000269|PubMed:11598371,
FT                   ECO:0000269|PubMed:11600539, ECO:0000269|PubMed:12788866,
FT                   ECO:0000269|PubMed:15110320, ECO:0000269|PubMed:7749410,
FT                   ECO:0000269|PubMed:8478006, ECO:0000269|PubMed:9497336"
FT                   /id="VAR_001301"
FT   VARIANT         483
FT                   /note="R -> Q (in AH3; dbSNP:rs200005406)"
FT                   /evidence="ECO:0000269|PubMed:12915679"
FT                   /id="VAR_018368"
FT   VARIANT         483
FT                   /note="R -> W (in AH3; salt wasting form;
FT                   dbSNP:rs759736443)"
FT                   /evidence="ECO:0000269|PubMed:14715874"
FT                   /id="VAR_026083"
FT   VARIANT         493
FT                   /note="N -> S (in allele CYP21A2*6; dbSNP:rs6473)"
FT                   /evidence="ECO:0000269|PubMed:10391209,
FT                   ECO:0000269|PubMed:10496074, ECO:0000269|PubMed:1406709,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:3038528,
FT                   ECO:0000269|PubMed:7749410"
FT                   /id="VAR_001302"
FT   MUTAGEN         268
FT                   /note="S->C,M,T: No loss of function."
FT                   /evidence="ECO:0000269|PubMed:1864962"
FT   MUTAGEN         281
FT                   /note="V->I: Normal KM but 50% reduced Vmax."
FT   MUTAGEN         281
FT                   /note="V->T: Normal KM but 10% reduced Vmax."
FT   MUTAGEN         428
FT                   /note="C->M,S,T: Loss of activity and loss of P450
FT                   absorption."
FT                   /evidence="ECO:0000269|PubMed:1864962"
FT   CONFLICT        155
FT                   /note="G -> D (in Ref. 7; BAB70774)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        242
FT                   /note="R -> G (in Ref. 7; BAB70774)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        277
FT                   /note="L -> Q (in Ref. 7; BAB70774)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        304
FT                   /note="V -> A (in Ref. 7; BAB70774)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        311
FT                   /note="P -> L (in Ref. 14; AAA59985)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        346
FT                   /note="N -> I (in Ref. 14; AAA59985)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        426
FT                   /note="R -> P (in Ref. 1; AAB59440)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        437
FT                   /note="E -> D (in Ref. 1; AAB59440)"
FT                   /evidence="ECO:0000305"
FT   HELIX           38..40
FT                   /evidence="ECO:0007829|PDB:4Y8W"
FT   HELIX           44..50
FT                   /evidence="ECO:0007829|PDB:4Y8W"
FT   HELIX           52..55
FT                   /evidence="ECO:0007829|PDB:4Y8W"
FT   STRAND          57..63
FT                   /evidence="ECO:0007829|PDB:4Y8W"
FT   STRAND          66..71
FT                   /evidence="ECO:0007829|PDB:4Y8W"
FT   HELIX           74..81
FT                   /evidence="ECO:0007829|PDB:4Y8W"
FT   TURN            82..84
FT                   /evidence="ECO:0007829|PDB:4Y8W"
FT   HELIX           85..88
FT                   /evidence="ECO:0007829|PDB:4Y8W"
FT   HELIX           95..99
FT                   /evidence="ECO:0007829|PDB:4Y8W"
FT   HELIX           114..128
FT                   /evidence="ECO:0007829|PDB:4Y8W"
FT   TURN            129..134
FT                   /evidence="ECO:0007829|PDB:4Y8W"
FT   HELIX           135..150
FT                   /evidence="ECO:0007829|PDB:4Y8W"
FT   HELIX           160..177
FT                   /evidence="ECO:0007829|PDB:4Y8W"
FT   HELIX           179..182
FT                   /evidence="ECO:0007829|PDB:4Y8W"
FT   TURN            183..185
FT                   /evidence="ECO:0007829|PDB:4Y8W"
FT   HELIX           187..201
FT                   /evidence="ECO:0007829|PDB:4Y8W"
FT   HELIX           204..211
FT                   /evidence="ECO:0007829|PDB:4Y8W"
FT   HELIX           213..216
FT                   /evidence="ECO:0007829|PDB:4Y8W"
FT   HELIX           223..245
FT                   /evidence="ECO:0007829|PDB:4Y8W"
FT   HELIX           256..261
FT                   /evidence="ECO:0007829|PDB:4Y8W"
FT   HELIX           278..309
FT                   /evidence="ECO:0007829|PDB:4Y8W"
FT   HELIX           311..324
FT                   /evidence="ECO:0007829|PDB:4Y8W"
FT   TURN            336..338
FT                   /evidence="ECO:0007829|PDB:4Y8W"
FT   HELIX           343..355
FT                   /evidence="ECO:0007829|PDB:4Y8W"
FT   STRAND          369..373
FT                   /evidence="ECO:0007829|PDB:4Y8W"
FT   STRAND          376..378
FT                   /evidence="ECO:0007829|PDB:4Y8W"
FT   STRAND          383..386
FT                   /evidence="ECO:0007829|PDB:4Y8W"
FT   HELIX           388..392
FT                   /evidence="ECO:0007829|PDB:4Y8W"
FT   TURN            395..397
FT                   /evidence="ECO:0007829|PDB:4Y8W"
FT   STRAND          398..400
FT                   /evidence="ECO:0007829|PDB:4Y8W"
FT   HELIX           406..409
FT                   /evidence="ECO:0007829|PDB:4Y8W"
FT   HELIX           431..446
FT                   /evidence="ECO:0007829|PDB:4Y8W"
FT   STRAND          449..457
FT                   /evidence="ECO:0007829|PDB:4Y8W"
FT   STRAND          478..482
FT                   /evidence="ECO:0007829|PDB:4Y8W"
SQ   SEQUENCE   494 AA;  55887 MW;  7E1FF83B59FBA136 CRC64;
     MLLLGLLLLP LLAGARLLWN WWKLRSLHLP PLAPGFLHLL QPDLPIYLLG LTQKFGPIYR
     LHLGLQDVVV LNSKRTIEEA MVKKWADFAG RPEPLTYKLV SKNYPDLSLG DYSLLWKAHK
     KLTRSALLLG IRDSMEPVVE QLTQEFCERM RAQPGTPVAI EEEFSLLTCS IICYLTFGDK
     IKDDNLMPAY YKCIQEVLKT WSHWSIQIVD VIPFLRFFPN PGLRRLKQAI EKRDHIVEMQ
     LRQHKESLVA GQWRDMMDYM LQGVAQPSME EGSGQLLEGH VHMAAVDLLI GGTETTANTL
     SWAVVFLLHH PEIQQRLQEE LDHELGPGAS SSRVPYKDRA RLPLLNATIA EVLRLRPVVP
     LALPHRTTRP SSISGYDIPE GTVIIPNLQG AHLDETVWER PHEFWPDRFL EPGKNSRALA
     FGCGARVCLG EPLARLELFV VLTRLLQAFT LLPSGDALPS LQPLPHCSVI LKMQPFQVRL
     QPRGMGAHSP GQNQ
//
